Erectile and Clitoral Dysfunction as Harbingers of Cardiovascular Disease: A Perspective

ED may flag cardiovascular disease years before symptoms — the evidence for women lags far behind

Journal: Medicina (Kaunas, Lithuania) | Published: 2026-02-22 | Type: Perspective/Review | PMID: 41752814 Authors: Priviero F, Hollis F, Wood SK, Uline M, Andersson K-E, Webb RC (University of South Carolina; Lund University) Funding/COI: University of South Carolina Institute for Cardiovascular Disease Research, US Department of Defense, NIH, Sexual Medicine Society of North America, ISSWSH. No conflicts of interest declared.

Summary

This perspective argues that vasculogenic erectile dysfunction in men and female sexual arousal disorder (FSAD) in women should be treated as early clinical signals of systemic cardiovascular disease, not merely quality-of-life problems. In men, the authors describe the evidence as robust: ED can precede coronary artery disease, stroke, and CV mortality by several years, creating a window for earlier risk-factor intervention. For women, a meta-analysis cited in the paper found approximately 1.5-fold increased odds of female sexual dysfunction (FSD) in those with CVD — but the authors themselves acknowledge this evidence is less mature, more heterogeneous, and lacks prospective longitudinal data linking objective genital vascular measures to hard cardiovascular outcomes.

Claims

Study Quality

This is a perspective piece, not a systematic review or meta-analysis. There is no formal literature search methodology, no PRISMA flowchart, no inclusion/exclusion criteria, and no quantitative synthesis. The authors draw selectively from the literature — including, by their own admission, "seminal studies from earlier decades for historical context." That framing is reasonable for a perspective, but it means the reader has no way to assess how representative the cited evidence is.

The authors deserve credit for being unusually candid about methodological limitations: they explicitly note that heterogeneity in how SD is defined (IIEF-derived scores vs. single questions in men; FSFI vs. other instruments in women) inflates cross-study variability and limits effect size comparisons. They also acknowledge that residual confounding from medications, depression, and multimorbidity could both exaggerate and obscure the true association depending on how carefully these factors are controlled. That level of self-critique is rare in a perspective piece and materially improves its credibility.

Red Flags

Strengths

Verdict

The men's half of this paper summarizes a well-established association with reasonable nuance. The women's half is honest about being underdeveloped but still pushes for clinical implementation before the evidence warrants it. As a perspective piece, it cannot be faulted for lacking primary data — that's not what perspectives do. What it can be faulted for is issuing symmetric clinical recommendations ("multidisciplinary care is warranted") when the underlying evidence is anything but symmetric. Read it for the men's evidence synthesis and the unusually candid limitations section. Treat the women's conclusions as a research agenda, not an established clinical signal.